[breadcrumb_custom]

How To Know If ProKidney Corp (NASDAQ:PROK) Is Expensive At $1.22.

In last trading session, ProKidney Corp (NASDAQ:PROK) saw 0.43 million shares changing hands with its beta currently measuring 1.17. Company’s recent per share price level of $1.22 trading at -$0.04 or -3.17% at ring of the bell on the day assigns it a market valuation of $81.91M. That closing price of PROK’s stock is at a discount of -1063.11% from its 52-week high price of $14.19 and is indicating a premium of 8.2% from its 52-week low price of $1.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.36 million shares which gives us an average trading volume of 879.26K if we extend that period to 3-months.

ProKidney Corp (NASDAQ:PROK) trade information

Upright in the red during last session for losing -3.17%, in the last five days PROK remained trading in the red while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $1.22 price level, adding 9.63% to its value on the day. ProKidney Corp’s shares saw a change of -31.46% in year-to-date performance and have moved -3.94% in past 5-day. ProKidney Corp (NASDAQ:PROK) showed a performance of -24.69% in past 30-days. Number of shares sold short was 13.37 million shares which calculate 18.15 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

ProKidney Corp (PROK) estimates and forecasts

Statistics highlight that ProKidney Corp is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -90.41% of value to its shares in past 6 months, showing an annual growth rate of -156.52% while that of industry is 11.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

PROK Dividends

ProKidney Corp is more likely to be releasing its next quarterly report in March and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

ProKidney Corp (NASDAQ:PROK)’s Major holders

Insiders are in possession of 21.03% of company’s total shares while institution are holding 55.00 percent of that, with stock having share float percentage of 69.65%. Investors also watch the number of corporate investors in a company very closely, which is 55.00% institutions for ProKidney Corp that are currently holding shares of the company. Social Capital Group LLC is the top institutional holder at PROK for having 13.27 million shares of worth $148.52 million. And as of Jun 29, 2023, it was holding 21.55% of the company’s outstanding shares.

The second largest institutional holder is Morgan Stanley, which was holding about 9.7 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 15.74% of outstanding shares, having a total worth of $108.49 million.

On the other hand, Morgan Stanley Inst Fd Inc-Growth Port and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 2.7 million shares of worth $30.2 million or 4.38% of the total outstanding shares. The later fund manager was in possession of 1.38 million shares on Aug 30, 2023, making its stake of worth around $11.86 million in the company or a holder of 2.24% of company’s stock.

On Key

Related Posts